PaCIFiC-CUP Classifies Cancer of Unknown Primary

Launched by SUN YAT-SEN UNIVERSITY · Nov 20, 2023

Keywords

ClinConnect Summary

The PaCIFiC-CUP trial is studying a new way to help diagnose cancers that don't have a known origin, often called cancer of unknown primary (CUP). Researchers are using advanced computer technology to analyze patterns in DNA from cancer samples. By looking at these patterns, they hope to better identify the type of cancer and its source, which can lead to more personalized and effective treatments for patients.

To participate in this study, you need to have a diagnosis of a tumor with an unknown primary site, and your tumor samples must come from a specific cancer center. You should also be in generally good health, with a performance status score of 0-2, which means you can carry out daily activities with little to no assistance. If you join the trial, you will undergo a series of standard medical tests to gather important information about your health and cancer. It’s important to note that pregnant or breastfeeding women and those with certain health issues or previous tumors may not be eligible. Overall, this trial aims to improve cancer diagnosis and treatment through innovative research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The patient specimens were obtained from the Sun Yat-sen University Cancer Center and affiliated cooperating centers, with written consent from the patients authorizing the use of the specimens for research purposes.
• • 2. Following standard assessments (medical history, physical examination, complete blood count, biochemistry, computed tomography scans of the neck, chest, abdomen, and pelvis, targeted evaluations of all symptomatic areas, pathology, and immunohistochemistry), the diagnosis was determined as a primary site unknown tumor (including adenocarcinoma, squamous cell carcinoma, undifferentiated carcinoma, neuroendocrine carcinoma, sarcoma, etc).
• • 3. The diagnosis was confirmed at the participating institution and the patient had received systemic therapy.
• • 4. Complete clinical, pathological, and follow-up data for the patients can be obtained.
• • 5. ECOG performance status score: 0-2 points.
• Exclusion Criteria:
• • 1. Pregnant or lactating female patients.
• • 2. Tumor tissue sample size is too small (tumor tissue accounts for \<70% in the biopsy or slice tissue).
• • 3. Organ transplant or history of non-autologous (allogeneic) bone marrow or stem cell transplantation.
• • 4. History of previous tumors, with the current condition being a recurrent tumor.
• • 5. Hematological malignancies (excluding lymphoma).
• • 6. Other diseases that may severely impact patient survival, such as severe cardiovascular or cerebrovascular diseases, sepsis, severe trauma or burns, etc.